D2/D3 receptor agonism: paving the way for a new therapeutic target for taste disorders in Parkinson’s disease and other conditions?

D2/D3 receptor agonism: paving the way for a new therapeutic target for taste disorders in Parkinson’s disease and other conditions?
Int J Neuropsychopharmacol. 2022 Jul 31:pyac042. doi: 10.1093/ijnp/pyac042. Online ahead of print.ABSTRACTChemosensory (i.e., olfaction and taste) dysfunction is common in neurodegenerative (e.g., Parkinson's disease, Alzheimer's disease, and dementia), psychiatric (e.g., depression, bipolar disorders, other conditions), post-infectious (i.e., long COVID) diseases and in the elderly. Despite its impact on patient's quality of life, no established treatment for taste disorders exists so ... read more
Source: PubMedPublished on 2022-07-31By Elisa Mantovani